A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

Cytotherapy

Volumn 14, Issue 7, 2012, Pages 830-840

  Shimasaki, Noriko ^a,b   Fujisaki, Hiroyuki ^a   Cho, Duck ^a   Masselli, Marika ^a   Lockey, Timothy ^a   Eldridge, Paul ^a   Leung, Wing ^a   Campana, Dario ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Acute lymphoblastic leukemia; Cell therapy; Natural killer cells; Non Hodgkin lymphoma

Indexed keywords

CD19 ANTIGEN; CD3ZETA ANTIGEN; GAMMA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MOLECULE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR XENOGRAFT;

EID: 84863915982     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.671519     Document Type: Article

References (39)

1. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-100.
2. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44-9.
3. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-Like receptor-Mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117:764-71.
4. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-9
5. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814-9.
6. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-Identical sibling hematopoietic stem-Cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878-84.
7. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411-9.
8. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood. 2005;105:3051-7.
9. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28: 955-9.
10. Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLAidentical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant. 2010;16:1257-64.
11. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172:644-50.
12. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-Leukemia activity of alloreactive NK cells in KIR ligand-Mismatched haploidentical HSCT for pediatric patients: Evaluation of the functional role of activating KIR and redefi nition of inhibitory KIR specifi city. Blood. 2009;113:3119-29.
13. Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Muller I, Handgretinger R, et al. Reconstitution of natural killer cell receptors infl uences natural killer activity and relapse rate after haploidentical transplantation of T- and B-Cell depleted grafts in children. Haematologica. 2010;95: 1381-8.
14. Cifaldi L, Lo ME, Forloni M, Giorda E, Lorenzi S, Petrini S, et al. Natural killer cells Efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res. 2011;71:1597-606.
15. Imai C, Iwamoto S, Campana D. Genetic modifi cation of primary natural killer cells overcomes inhibitory signals and induces specifi c killing of leukemic cells. Blood. 2005;106: 376-83.
16. Manabe A, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Pui CH, et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-Risk acute lymphoblastic leukemia. Blood. 1994;83:1731-7.
17. Harmon JM, Norman MR, Fowlkes BJ, Thompson EB. Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line. J Cell Physiol. 1979;98:267-78.
18. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010-7.
19. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009;69:4010-7.
20. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16:3901-9.
21. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676-84.
22. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-Compliant non-Viral method. Cancer Gene Ther. 2010;17:147-54.
23. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003;120: 846-9.
24. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190:167-72.
25. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423-32.
26. Kustikova O, Brugman M, Baum C. The genomic risk of somatic gene therapy. Semin Cancer Biol. 2010;20:269-78.
27. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3: 35-45.
28. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
29. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: Tools, trials and tribulations. Nat Rev Immunol. 2009;9: 704-16
30. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010;22:251-7.
31. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-Modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-33.
32. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, et al. Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther. 2006;17:1027-35.
33. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70:9053-61.
34. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010; 70:9554-61.
35. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-41.
36. Faderl S, O' Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, et al. Adult acute lymphoblastic leukemia: Concepts and strategies. Cancer. 2010;116:1165-76.
37. Gribben JG, O' B rien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29:544-50.
38. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008;168:469-76.
39. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243:59-75.